Full Press Release Details
Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statement of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
| As at | Note | June 30, 2023 | December 31, 2022 | ||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | 185,455 | 279,586 | |||||
| Restricted cash | 19,456 | 19,338 | |||||
| Marketable securities | 6 | 3,535 | 21,926 | ||||
| Accounts receivable | 32,661 | 22,636 | |||||
| Biological assets | 7 | 1,330 | 3,477 | ||||
| Inventory | 8 | 160,407 | 127,782 | ||||
| Prepaid expenses and deposits | 21,792 | 10,110 | |||||
| Investments | 14 | 23,038 | 6,552 | ||||
| Assets held for sale | 3(a),9 | 8,391 | 6,375 | ||||
| Net investment in subleases | 12 | 3,656 | 3,701 | ||||
| 459,721 | 501,483 | ||||||
| Non-current assets | |||||||
| Long-term deposits | 9,766 | 8,584 | |||||
| Right of use assets | 10 | 136,947 | 134,154 | ||||
| Property, plant and equipment | 11 | 181,841 | 143,409 | ||||
| Net investment in subleases | 12 | 18,918 | 19,618 | ||||
| Intangible assets | 13 | 74,446 | 74,885 | ||||
| Investments | 14 | 9,638 | 90,702 | ||||
| Equity-accounted investees | 15 | 532,818 | 519,255 | ||||
| Goodwill | 3(a) | 147,680 | 67,260 | ||||
| Total assets | 1,571,775 | 1,559,350 | |||||
| Liabilities | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | 62,557 | 48,153 | |||||
| Lease liabilities | 17 | 35,982 | 30,206 | ||||
| Derivative warrants | 16 | 3,960 | 11,002 | ||||
| 102,499 | 89,361 | ||||||
| Non-current liabilities | |||||||
| Lease liabilities | 17 | 136,136 | 139,625 | ||||
| Other liabilities | 5,252 | 2,709 | |||||
| Total liabilities | 243,887 | 231,695 | |||||
| Shareholders' equity | |||||||
| Share capital | 18(b) | 2,365,845 | 2,292,810 | ||||
| Warrants | 2,260 | 2,260 | |||||
| Contributed surplus | 73,636 | 68,961 | |||||
| Contingent consideration | 2,279 | 2,279 | |||||
| Accumulated deficit | (1,156,279 | ) | (1,091,999 | ) | |||
| Accumulated other comprehensive income | 20,182 | 32,188 | |||||
| Total shareholders' equity | 1,307,923 | 1,306,499 | |||||
| Non-controlling interest | 19,965 | 21,156 | |||||
| Total liabilities and shareholders' equity | 1,571,775 | 1,559,350 |
Commitments (note 27)
Subsequent events (notes 19 and 28)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||
| Note | 2023 | 2022 | 2023 | 2022 | ||||||||||||||
| Gross revenue | 20 | 257,425 | 227,557 | 470,324 | 247,684 | |||||||||||||
| Excise taxes | 12,914 | 3,862 | 23,361 | 6,392 | ||||||||||||||
| Net revenue | 244,511 | 223,695 | 446,963 | 241,292 | ||||||||||||||
| Cost of sales | 8 | 188,922 | 174,291 | 347,071 | 188,617 | |||||||||||||
| Inventory impairment and obsolescence | 8 | 4,291 | 3,871 | 13,468 | 5,852 | |||||||||||||
| Gross margin before fair value adjustments | 51,298 | 45,533 | 86,424 | 46,823 | ||||||||||||||
| Change in fair value of biological assets | (1,413 | ) | (388 | ) | (4,948 | ) | 3,302 | |||||||||||
| Change in fair value realized through inventory | 2,048 | (2,066 | ) | 2,998 | (3,627 | ) | ||||||||||||
| Gross margin | 51,933 | 43,079 | 84,474 | 46,498 | ||||||||||||||
| Interest and fee revenue | 21 | 3,421 | 2,577 | 7,632 | 6,438 | |||||||||||||
| Investment loss | 21 | (4,020 | ) | (35,073 | ) | (9,189 | ) | (52,783 | ) | |||||||||
| Share of profit (loss) of equity-accounted investees | 15 | (936 | ) | (37,978 | ) | 8,580 | (33,887 | ) | ||||||||||
| General and administrative | 52,727 | 40,293 | 101,300 | 50,975 | ||||||||||||||
| Sales and marketing | 4,104 | 3,132 | 7,490 | 4,243 | ||||||||||||||
| Research and development | 20 | 390 | 160 | 485 | ||||||||||||||
| Depreciation and amortization | 10,11,13 | 13,443 | 8,800 | 29,911 | 9,539 | |||||||||||||
| Share-based compensation | 19 | 3,893 | 438 | 6,102 | 4,642 | |||||||||||||
| Restructuring costs | 4,042 | (882 | ) | 5,578 | (882 | ) | ||||||||||||
| Asset impairment | 11,13 | 1,658 | 1,850 | 2,465 | 1,850 | |||||||||||||
| Loss from operations | (29,489 | ) | (81,416 | ) | (61,509 | ) | (104,586 | ) | ||||||||||
| Transaction costs | (173 | ) | 7,938 | (2,213 | ) | 1,457 | ||||||||||||
| Finance costs, net | 22 | (2,458 | ) | (26,505 | ) | (7,631 | ) | (26,444 | ) | |||||||||
| Change in estimate of fair value of derivative warrants | 16 | 2,240 | 23,656 | 7,042 | 15,356 | |||||||||||||
| Foreign exchange gain (loss) | (31 | ) | 161 | (194 | ) | 11 | ||||||||||||
| Gain (loss) on disposition of assets | (77 | ) | 402 | (261 | ) | 402 | ||||||||||||
| Loss before income tax | (29,988 | ) | (75,764 | ) | (64,766 | ) | (113,804 | ) | ||||||||||
| Income tax recovery | 1,791 | 1,791 | ||||||||||||||||
| Net loss from continuing operations | (29,988 | ) | (73,973 | ) | (64,766 | ) | (112,013 | ) | ||||||||||
| Net loss from discontinued operations | 4 | (3,170 | ) | (4,535 | ) | |||||||||||||
| Net loss | (33,158 | ) | (73,973 | ) | (69,301 | ) | (112,013 | ) | ||||||||||
| Equity-accounted investees - share of other comprehensive income (loss) | 15 | (11,621 | ) | 12,727 | (12,006 | ) | 5,994 | |||||||||||
| Gain on translation of foreign operations | (5 | ) | ||||||||||||||||
| Comprehensive loss | (44,784 | ) | (61,246 | ) | (81,307 | ) | (106,019 | ) | ||||||||||
| Net loss from continuing operations attributable to: | ||||||||||||||||||
| Owners of the Company | (29,350 | ) | (73,301 | ) | (63,553 | ) | (111,205 | ) | ||||||||||
| Non-controlling interest | (638 | ) | (672 | ) | (1,213 | ) | (808 | ) | ||||||||||
| (29,988 | ) | (73,973 | ) | (64,766 | ) | (112,013 | ) | |||||||||||
| Net income (loss) attributable to: | ||||||||||||||||||
| Owners of the Company | (32,520 | ) | (73,301 | ) | (68,088 | ) | (111,205 | ) | ||||||||||
| Non-controlling interest | (638 | ) | (672 | ) | (1,213 | ) | (808 | ) | ||||||||||
| (33,158 | ) | (73,973 | ) | (69,301 | ) | (112,013 | ) | |||||||||||
| Comprehensive income (loss) attributable to: | ||||||||||||||||||
| Owners of the Company | (44,146 | ) | (60,574 | ) | (80,094 | ) | (105,211 | ) | ||||||||||
| Non-controlling interest | (638 | ) | (672 | ) | (1,213 | ) | (808 | ) | ||||||||||
| (44,784 | ) | (61,246 | ) | (81,307 | ) | (106,019 | ) | |||||||||||
| Net loss per common share attributable to owners of the Company | ||||||||||||||||||
| Basic and diluted | 24 | $ | (0.12 | ) | $ | (0.31 | ) | $ | (0.26 | ) | $ | (0.50 | ) |
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
| Note | Share capital | Warrants | Contributed surplus | Contingent consideration | Accumulated deficit | Accumulated other comprehensive income | Non-controlling interest | Total | |||||||||||||||||
| Balance at December 31, 2022 | 2,292,810 | 2,260 | 68,961 | 2,279 | (1,091,999 | ) | 32,188 | 21,156 | 1,327,655 | ||||||||||||||||
| Net loss | (68,088 | ) | (1,213 | ) | (69,301 | ) | |||||||||||||||||||
| Other comprehensive loss | (12,006 | ) | (12,006 | ) | |||||||||||||||||||||
| Share repurchases | 18(b) | (5,344 | ) | 3,808 | (1,536 | ) | |||||||||||||||||||
| Share issuances by subsidiaries | 25 | 26 | 51 | ||||||||||||||||||||||
| Acquisition | 3(a) | 83,953 | 83,953 | ||||||||||||||||||||||
| Shares acquired and cancelled | 18(b) | (6,615 | ) | (6,615 | ) | ||||||||||||||||||||
| Share-based compensation | 19 | 5,691 | 5,691 | ||||||||||||||||||||||
| Employee awards exercised | 18(b) | 1,041 | (1,041 | ) | |||||||||||||||||||||
| Distribution declared by subsidiaries | (4 | ) | (4 | ) | |||||||||||||||||||||
| Balance at June 30, 2023 | 2,365,845 | 2,260 | 73,636 | 2,279 | (1,156,279 | ) | 20,182 | 19,965 | 1,327,888 | ||||||||||||||||
| Balance at March 31, 2023 | 2,365,319 | 2,260 | 70,716 | 2,279 | (1,123,759 | ) | 31,808 | 20,587 | 1,369,210 | ||||||||||||||||
| Net loss | (32,520 | ) | (638 | ) | (33,158 | ) | |||||||||||||||||||
| Other comprehensive income | (11,626 | ) | (11,626 | ) | |||||||||||||||||||||
| Share issuances by subsidiaries | 37 | 22 | 59 | ||||||||||||||||||||||
| Share-based compensation | 19 | 3,409 | 3,409 | ||||||||||||||||||||||
| Employee awards exercised | 18(b) | 526 | (526 | ) | |||||||||||||||||||||
| Distribution declared by subsidiaries | (6 | ) | (6 | ) | |||||||||||||||||||||
| Balance at June 30, 2023 | 2,365,845 | 2,260 | 73,636 | 2,279 | (1,156,279 | ) | 20,182 | 19,965 | 1,327,888 |
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
| Note | Share capital | Warrants | Contributed surplus | Contingent consideration | Accumulated deficit | Accumulated other comprehensive income | Non- controlling interest | Total equity | |||||||||||||||||
| Balance at December 31, 2021 | 2,035,704 | 8,092 | 60,734 | 2,279 | (785,112 | ) | 7,607 | 229 | 1,329,533 | ||||||||||||||||
| Net loss | (111,205 | ) | (808 | ) | (112,013 | ) | |||||||||||||||||||
| Other comprehensive income | 5,994 | 5,994 | |||||||||||||||||||||||
| Share issuances | 2,870 | 2,870 | |||||||||||||||||||||||
| Share repurchases | (5,170 | ) | 3,117 | (2,053 | ) | ||||||||||||||||||||
| Share issuances by subsidiaries | 57 | 35 | 92 | ||||||||||||||||||||||
| Acquisition | 287,129 | 58,250 | 345,379 | ||||||||||||||||||||||
| Share-based compensation | 5,992 | 95 | 6,087 | ||||||||||||||||||||||
| Employee awards exercised | 1,740 | (1,740 | ) | ||||||||||||||||||||||
| Balance at June 30, 2022 | 2,322,273 | 8,092 | 65,043 | 2,279 | (893,200 | ) | 13,601 | 57,801 | 1,575,889 | ||||||||||||||||
| Balance at March 31, 2022 | 2,327,443 | 8,092 | 61,959 | 2,279 | (823,016 | ) | 874 | 58,343 | 1,635,974 | ||||||||||||||||
| Net loss | (73,301 | ) | (672 | ) | (73,973 | ) | |||||||||||||||||||
| Other comprehensive income | 12,727 | 12,727 | |||||||||||||||||||||||
| Share repurchases | (5,170 | ) | 3,117 | (2,053 | ) | ||||||||||||||||||||
| Share issuances by subsidiaries | 57 | 35 | 92 | ||||||||||||||||||||||
| Share-based compensation | 3,027 | 95 | 3,122 | ||||||||||||||||||||||
| Balance at June 30, 2022 | 2,322,273 | 8,092 | 65,043 | 2,279 | (893,200 | ) | 13,601 | 57,801 | 1,575,889 |
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||||
| Note | 2023 | 2022 | 2023 | 2022 | ||||||||||||||
| Cash provided by (used in): | ||||||||||||||||||
| Operating activities | ||||||||||||||||||
| Net loss for the period | (33,158 | ) | (73,973 | ) | (69,301 | ) | (112,013 | ) | ||||||||||
| Adjustments for: | ||||||||||||||||||
| Income tax recovery | (1,791 | ) | (1,791 | ) | ||||||||||||||
| Interest and fee revenue | 21 | (3,421 | ) | (2,577 | ) | (7,632 | ) | (6,438 | ) | |||||||||
| Change in fair value of biological assets | 1,413 | 388 | 4,948 | (3,302 | ) | |||||||||||||
| Share-based compensation | 19 | 3,893 | 438 | 6,102 | 4,642 | |||||||||||||
| Depreciation and amortization | 10,11,13 | 14,674 | 10,538 | 32,933 | 12,977 | |||||||||||||
| Loss (gain) on disposition of assets | 77 | (402 | ) | 261 | (402 | ) | ||||||||||||
| Inventory obsolescence | 8 | 4,291 | 3,871 | 13,468 | 5,852 | |||||||||||||
| Finance costs | 22 | 2,458 | 26,505 | 7,631 | 26,444 | |||||||||||||
| Change in estimate of fair value of derivative warrants | 16 | (2,240 | ) | (23,656 | ) | (7,042 | ) | (15,356 | ) | |||||||||
| Unrealized foreign exchange loss (gain) | (72 | ) | 19 | (24 | ) | 35 | ||||||||||||
| Asset impairment | 1,658 | 1,850 | 2,465 | 1,850 | ||||||||||||||
| Share of (profit) loss of equity-accounted investees | 15 | 936 | 37,978 | (8,580 | ) | 33,887 | ||||||||||||
| Loss on settlement of marketable securities | 6,21 | 48,988 | 92,792 | |||||||||||||||
| Unrealized (gain) loss on marketable securities | 6,21 | (44,968 | ) | 35,338 | (83,603 | ) | 53,172 | |||||||||||
| Additions to marketable securities | (2,899 | ) | (3,500 | ) | ||||||||||||||
| Proceeds from settlement of marketable securities | 6 | 3,437 | 3,463 | |||||||||||||||
| Income distributions from equity-accounted investees | 685 | |||||||||||||||||
| Interest received | 3,217 | 2,084 | 6,920 | 5,799 | ||||||||||||||
| Change in non-cash working capital | 23 | (14,193 | ) | (31,584 | ) | (56,755 | ) | (46,434 | ) | |||||||||
| Net cash used in operating activities from continuing operations | (13,010 | ) | (17,873 | ) | (61,954 | ) | (43,893 | ) | ||||||||||
| Net cash provided by operating activities from discontinued operations | 4 | 4,167 | 4,314 | |||||||||||||||
| Net cash used in operating activities | (8,843 | ) | (17,873 | ) | (57,640 | ) | (43,893 | ) | ||||||||||
| Investing activities | ||||||||||||||||||
| Additions to property, plant and equipment | 11 | (1,247 | ) | (3,554 | ) | (2,641 | ) | (4,535 | ) | |||||||||
| Additions to intangible assets | 13 | (39 | ) | 1 | (56 | ) | (55 | ) | ||||||||||
| Additions to investments | 125 | 337 | (702 | ) | (14,094 | ) | ||||||||||||
| Additions to equity-accounted investees | 15 | (9,443 | ) | (36,880 | ) | (16,989 | ) | (94,200 | ) | |||||||||
| Proceeds from disposal of property, plant and equipment | 55 | 4,000 | 137 | 4,000 | ||||||||||||||
| Acquisitions, net of cash acquired | 3 | 3,695 | (31,149 | ) | ||||||||||||||
| Change in non-cash working capital | 23 | 1,586 | 294 | 1,127 | 259 | |||||||||||||
| Net cash used in investing activities from continuing operations | (8,963 | ) | (35,802 | ) | (15,429 | ) | (139,774 | ) | ||||||||||
| Net cash used in investing activities from discontinued operations | 4 | |||||||||||||||||
| Net cash used in investing activities | (8,963 | ) | (35,802 | ) | (15,429 | ) | (139,774 | ) | ||||||||||
| Financing activities | ||||||||||||||||||
| Change in restricted cash | (76 | ) | 2,541 | (118 | ) | 7,607 | ||||||||||||
| Payments on lease liabilities, net | (10,116 | ) | (9,177 | ) | (19,607 | ) | (9,624 | ) | ||||||||||
| Repurchase of common shares, net of costs | 18(b) | (2,053 | ) | (1,536 | ) | (2,053 | ) | |||||||||||
| Repayment of long-term debt | (10,000 | ) | ||||||||||||||||
| Change in non-cash working capital | 23 | 200 | 2,170 | 199 | 2,116 | |||||||||||||
| Net cash used in financing activities from continuing operations | (9,992 | ) | (6,519 | ) | (21,062 | ) | (11,954 | ) | ||||||||||
| Net cash used in financing activities from discontinued operations | 4 | |||||||||||||||||
| Net cash used in financing activities | (9,992 | ) | (6,519 | ) | (21,062 | ) | (11,954 | ) | ||||||||||
| Change in cash and cash equivalents | (27,798 | ) | (60,194 | ) | (94,131 | ) | (195,621 | ) | ||||||||||
| Cash and cash equivalents, beginning of period | 213,253 | 422,824 | 279,586 | 558,251 | ||||||||||||||
| Cash and cash equivalents, end of period | 185,455 | 362,630 | 185,455 | 362,630 |
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company's shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from Sundial Growers Inc. to SNDL Inc. .
The Company's head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis domestically and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company also owns approximately 63% of Nova Cannabis Inc. ( Nova ) (TSX: NOVC), whose principal activities are the retail sale of cannabis.
SNDL and its subsidiaries currently operate solely in Canada, with the exception of Green Roads, Inc. ( Green Roads ), a subsidiary acquired in the Valens Transaction (defined below) who sold CBD products in the United States and is classified as held for sale (note 9) and discontinued operations (note 4). Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 15), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's common shares trade on the Nasdaq Capital Market ( Nasdaq ) under the ticker symbol SNDL .
2.Basis of presentation
Statement of compliance
The condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the annual consolidated financial statements for the year ended December 31, 2022. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2022.
These financial statements were approved and authorized for issue by the Board of Directors ( Board ) on August 11, 2023.
3.Business acquisitions
On January 17, 2023, the Company acquired all of the issued and outstanding common shares of The Valens Company Inc. ( Valens ), other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the Valens Transaction ). The Valens Transaction consideration was comprised of (i) the assumption of Valens' $60 million non-revolving term loan facility from its then existing lender, and (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share).
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments.
The Company has engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts. The purchase price allocation is not final as the Company is continuing to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment.
The fair value of consideration paid was as follows:
| Provisional | Adjustments | Provisional | |||||||
| Valens loan facility | 61,512 | 61,512 | |||||||
| Issuance of common shares | 83,953 | 83,953 | |||||||
| 145,465 | 145,465 |
The preliminary fair value of the assets and liabilities acquired was as follows:
| Provisional | Adjustments | Provisional | |||||||
| Cash | 3,615 | 3,615 | |||||||
| Accounts receivable | 21,361 | 21,361 | |||||||
| Investments | 876 | 876 | |||||||
| Prepaid expenses and deposits | 4,980 | 4,980 | |||||||
| Inventory | 14,140 | 14,140 | |||||||
| Assets held for sale | 6,330 | 6,330 | |||||||
| Right of use assets | 2,882 | 2,882 | |||||||
| Property, plant and equipment | 63,030 | (10,938 | ) | 52,092 | |||||
| Intangible assets | 2,285 | (785 | ) | 1,500 | |||||
| Goodwill | 68,697 | 11,723 | 80,420 | ||||||
| Accounts payable and accrued liabilities | (34,185 | ) | (34,185 | ) | |||||
| Contractual obligation | (5,339 | ) | (5,339 | ) | |||||
| Lease liabilities | (3,207 | ) | (3,207 | ) | |||||
| 145,465 | 145,465 |
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, identifies adjustments to the above amounts, the accounting for the acquisition will be revised.
Valens subsidiary Green Roads was sold and has been classified as held for sale and discontinued operations (note 4).
The financial statements incorporate the operations of Valens commencing January 18, 2023. During the period January 18, 2023 to June 30, 2023 the Company recorded revenues of $39.1 million and net loss of $25.8 million from the Valens operations. Had the Valens Transaction closed on January 1, 2023, management estimates that for the period January 1, 2023, to January 17, 2023, revenue would have increased by $4.2 million and net loss would have increased by $2.1 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2023.
The Company incurred costs related to the Valens Transaction of $2.6 million which have been included in transaction costs.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
On February 7, 2023, the Company acquired the right, title and interest in (i) five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the Superette IP ); and (iii) the shares of Superette Ontario (collectively, the Superette Transaction ).
The Superette acquisition consideration was comprised of the extinguishment of the Company's promissory note.
The fair value of consideration paid was as follows:
| Extinguishment of promissory note | 2,625 | ||
| 2,625 |
The fair value of the assets and liabilities acquired was as follows:
| Cash | 80 | ||
| Accounts receivable | 30 | ||
| Prepaid expenses and deposits | 141 | ||
| Inventory | 371 | ||
| Right of use assets | 1,129 | ||
| Property, plant and equipment | 2,077 | ||
| Accounts payable and accrued liabilities | (74 | ) | |
| Lease liabilities | (1,129 | ) | |
| 2,625 |
The financial statements incorporate the operations of Superette commencing February 8, 2023. During the period February 8, 2023 to June 30, 2023 the Company recorded revenues of $1.7 million and net loss of $0.7 million from the Superette operations. Had the Superette Transaction closed on January 1, 2023, management estimates that for the period January 1, 2023, to February 7, 2023, revenue would have increased by $0.5 million and net loss would have increased by $0.1 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2023.
The Company incurred costs related to the Superette Transaction of $0.6 million which have been included in transaction costs.
4.Discontinued operations
The Green Roads operations acquired as part of the Valens acquisition were classified as held for sale and discontinued operations as the carrying amount of the disposal group was expected to be recovered through a sale transaction rather than through continued use.
Green Roads filed for bankruptcy on March 6, 2023. Subject to the bid procedures, a successful bid of USD$3.1 million was accepted and the sale was approved at a court hearing on May 10, 2023. The disposition of Green Roads closed on May 31, 2023 and a loss on disposition of $2.3 million was recorded.
The consolidated statement of loss and comprehensive loss and consolidated statement of cash flows have been presented to show the discontinued operations separately from continuing operations.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Results of discontinued operations
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net revenue | 2,978 | 7,510 | ||||||||||||||
| Cost of sales | 1,640 | 3,841 | ||||||||||||||
| Gross margin | 1,338 | 3,669 | ||||||||||||||
| General and administrative | 1,302 | 3,639 | ||||||||||||||
| Sales and marketing | 687 | 1,817 | ||||||||||||||
| Depreciation and amortization | 231 | 450 | ||||||||||||||
| Loss from operations | (882 | ) | (2,237 | ) | ||||||||||||
| Finance costs | (6 | ) | (16 | ) | ||||||||||||
| Loss on disposition | (2,282 | ) | (2,282 | ) | ||||||||||||
| Net loss | (3,170 | ) | (4,535 | ) |
5.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
| Liquor Retail | Cannabis Retail (1) | Cannabis Operations (2) | Investments (3) | Corporate | Total | |||||||||||||||||||
| As at June 30, 2023 | ||||||||||||||||||||||||
| Total assets | 339,097 | 204,016 | 318,028 | 691,178 | 19,456 | 1,571,775 | ||||||||||||||||||
| Six months ended June 30, 2023 | ||||||||||||||||||||||||
| Net revenue | 267,601 | 139,289 | 40,073 | 446,963 | ||||||||||||||||||||
| Gross margin | 61,627 | 33,599 | (10,752 | ) | 84,474 | |||||||||||||||||||
| Interest and fee revenue | 58 | 7,397 | 177 | 7,632 | ||||||||||||||||||||
| Investment (loss) income | (497 | ) | (8,692 | ) | (9,189 | ) | ||||||||||||||||||
| Share of profit (loss) of equity-accounted investees | 8,580 | 8,580 | ||||||||||||||||||||||
| Depreciation and amortization | 18,507 | 7,051 | 1,796 | 2,557 | 29,911 | |||||||||||||||||||
| Earnings (loss) from operations | 6,271 | 2,287 | (32,821 | ) | 7,077 | (44,323 | ) | (61,509 | ) | |||||||||||||||
| Income (loss) before income tax | 3,751 | 477 | (32,951 | ) | 3,453 | (39,496 | ) | (64,766 | ) | |||||||||||||||
| Three months ended June 30, 2023 | ||||||||||||||||||||||||
| Net revenue | 151,690 | 71,881 | 20,940 | 244,511 | ||||||||||||||||||||
| Gross margin | 35,360 | 17,780 | (1,207 | ) | 51,933 | |||||||||||||||||||
| Interest and fee revenue | 58 | 3,186 | 177 | 3,421 | ||||||||||||||||||||
| Investment (loss) income | (214 | ) | (3,806 | ) | (4,020 | ) | ||||||||||||||||||
| Share of profit (loss) of equity-accounted investees | (936 | ) | (936 | ) | ||||||||||||||||||||
| Depreciation and amortization | 8,161 | 3,361 | 650 | 1,271 | 13,443 | |||||||||||||||||||
| Earnings (loss) from operations | 8,207 | 2,340 | (14,134 | ) | (1,660 | ) | (24,242 | ) | (29,489 | ) | ||||||||||||||
| Income (loss) before income tax | 6,714 | 1,221 | (13,831 | ) | (1,917 | ) | (22,175 | ) | (29,988 | ) |
(1)Cannabis retail includes the operations of Superette for the period February 8, 2023 to June 30, 2023.
(2)Cannabis operations includes the operations of Valens for the period January 18, 2023 to June 30, 2023.
(3)Total assets include cash and cash equivalents.
| Liquor Retail (1) | Cannabis Retail (1) | Cannabis Operations | Investments (2) | Corporate | Total | |||||||||||||||||||
| As at December 31, 2022 | ||||||||||||||||||||||||
| Total assets | 351,338 | 200,393 | 163,130 | 825,151 | 19,338 | 1,559,350 | ||||||||||||||||||
| Six months ended June 30, 2022 | ||||||||||||||||||||||||
| Net revenue | 149,947 | 71,006 | 20,339 | 241,292 | ||||||||||||||||||||
| Gross margin | 33,812 | 17,190 | (4,504 | ) | 46,498 | |||||||||||||||||||
| Interest and fee revenue | 6,438 | 6,438 | ||||||||||||||||||||||
| Investment loss | (52,783 | ) | (52,783 | ) | ||||||||||||||||||||
| Share of profit (loss) of equity-accounted investees | (33,887 | ) | (33,887 | ) | ||||||||||||||||||||
| Depreciation and amortization | 2,799 | 2,842 | 9 | 3,889 | 9,539 | |||||||||||||||||||
| Earnings (loss) from operations | 11,215 | 1,196 | (11,257 | ) | (79,668 | ) | (26,072 | ) | (104,586 | ) | ||||||||||||||
| Income (loss) before income tax | 8,306 | 167 | (11,000 | ) | (101,973 | ) | (9,304 | ) | (113,804 | ) | ||||||||||||||
| Three months ended June 30, 2022 | ||||||||||||||||||||||||
| Net revenue | 148,637 | 63,494 | 11,564 | 223,695 | ||||||||||||||||||||
| Gross margin | 33,528 | 13,897 | (4,346 | ) | 43,079 | |||||||||||||||||||
| Interest and fee revenue | 2,577 | 2,577 | ||||||||||||||||||||||
| Investment loss | (35,073 | ) | (35,073 | ) | ||||||||||||||||||||
| Share of profit (loss) of equity-accounted investees | (37,978 | ) | (37,978 | ) | ||||||||||||||||||||
| Depreciation and amortization | 2,799 | 2,247 | 3,754 | 8,800 | ||||||||||||||||||||
| Earnings (loss) from operations | 11,288 | 1,476 | (8,293 | ) | (69,973 | ) | (15,914 | ) | (81,416 | ) | ||||||||||||||
| Income (loss) before income tax | 8,379 | 447 | (8,036 | ) | (92,278 | ) | 15,724 | (75,764 | ) |
(1)Liquor retail includes operations of Alcanna Inc. ( Alcanna ) retail stores for the period March 31, 2022 to June 30, 2022, and cannabis retail includes operations of Nova retail stores for the period March 31, 2022 to June 30, 2022.
(2)Total assets include cash and cash equivalents.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Geographical disclosure
As at June 30, 2023, the Company had non-current assets related to investment credit operations in the United States of $532.8 million (December 31, 2022 $519.3 million). For the six months ended June 30, 2023, share of profit of equity-accounted investees related to operations in the United States was a gain of $8.6 million (six months ended June 30, 2022 loss of $33.9 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
6.Marketable securities
| As at | June 30, 2023 | December 31, 2022 | ||||
| Balance, beginning of year | 21,926 | 83,724 | ||||
| Acquisition (note 3(a)) | 876 | |||||
| Additions | 3,755 | |||||
| Dispositions | (10,078 | ) | ||||
| Change in fair value recognized in profit or loss | (9,189 | ) | (65,553 | ) | ||
| Balance, end of period | 3,535 | 21,926 |
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
| As at | June 30, 2023 | December 31, 2022 | ||||
| Balance, beginning of year | 3,477 | 4,410 | ||||
| Increase in biological assets due to capitalized costs | 15,214 | 27,749 | ||||
| Acquisition | 909 | |||||
| Net change in fair value of biological assets | (4,948 | ) | (1,309 | ) | ||
| Transferred to inventory upon harvest | (12,413 | ) | (28,282 | ) | ||
| Balance, end of period | 1,330 | 3,477 |
Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:
| Assumption | Input | Weighted average input | Effect of 10% change ($000s) | ||||||||||
| June 30 2023 | December 31 2022 | June 30 2023 | December 31 2022 | ||||||||||
| Yield per square foot of growing space (1) | Grams | 48 | 48 | 83 | 279 | ||||||||
| Average net selling price (2) | $/gram | 5.62 | 4.66 | 221 | 687 | ||||||||
| After harvest cost to complete and sell | $/gram | 1.15 | 1.27 | 47 | 187 |
(1)Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.